Organogenesis Holdings Inc. (NASDAQ:ORGO) Stock Holdings Boosted by SG Americas Securities LLC

SG Americas Securities LLC raised its position in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 23.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 35,774 shares of the company’s stock after purchasing an additional 6,727 shares during the quarter. SG Americas Securities LLC’s holdings in Organogenesis were worth $146,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in Organogenesis by 8.9% during the 3rd quarter. BlackRock Inc. now owns 10,536,761 shares of the company’s stock valued at $34,139,000 after purchasing an additional 861,588 shares in the last quarter. Soleus Capital Management L.P. boosted its stake in Organogenesis by 13.5% during the 4th quarter. Soleus Capital Management L.P. now owns 7,363,063 shares of the company’s stock valued at $19,807,000 after purchasing an additional 874,000 shares in the last quarter. Morgan Stanley boosted its stake in Organogenesis by 633.5% during the 3rd quarter. Morgan Stanley now owns 6,940,544 shares of the company’s stock valued at $22,071,000 after purchasing an additional 5,994,373 shares in the last quarter. State Street Corp boosted its stake in Organogenesis by 39.6% during the 2nd quarter. State Street Corp now owns 6,170,589 shares of the company’s stock valued at $30,112,000 after purchasing an additional 1,750,534 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Organogenesis by 7.0% during the 1st quarter. Vanguard Group Inc. now owns 4,605,257 shares of the company’s stock valued at $35,092,000 after purchasing an additional 303,243 shares in the last quarter. 49.57% of the stock is owned by institutional investors.

Organogenesis Price Performance

ORGO opened at $2.86 on Wednesday. Organogenesis Holdings Inc. has a 1 year low of $1.79 and a 1 year high of $4.70. The stock has a fifty day moving average price of $3.08 and a 200 day moving average price of $3.09. The company has a current ratio of 2.80, a quick ratio of 2.44 and a debt-to-equity ratio of 0.22. The stock has a market cap of $377.41 million, a price-to-earnings ratio of 71.52 and a beta of 1.57.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ORGO. BTIG Research increased their price objective on Organogenesis from $4.00 to $6.00 and gave the company a “buy” rating in a research report on Wednesday, December 27th. Cantor Fitzgerald restated an “overweight” rating and issued a $5.00 target price on shares of Organogenesis in a report on Friday, March 1st.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.